MedTrace Logo

Therapeutic Adherence in Uncontrolled Arterial Hypertension

NCT04464746 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2025-06-05

No results posted yet for this study

Summary

In hypertension, highly prevalent, up to 10-15% of hypertensive patients have uncontrolled blood pressure despite being treated with ≥3 drugs, which is known as resistant hypertension. Resistant arterial hypertension, together with difficult-to-control hypertension, has a worse cardiovascular prognosis than controlled hypertension. In addition, data on therapeutic adherence in arterial hypertension show that 1 in 2 hypertensive patients do not fully or partially comply with the indicated therapeutic prescription. The determination of antihypertensive drugs or their metabolites in urine seems to be a good indicator of therapeutic adherence. On the other hand, the implementation of a specific program to improve knowledge of the disease and its risks and promote therapeutic adherence could improve the control of hypertension and reduce the associated morbidity and mortality.

Conditions

  • Treatment Adherence

Interventions

OTHER

implementation of a specific program to improve therapeutic adherence

1. Discussion of risks associated with high BP;aims,healthy lifestyle options. 2. Individualized educational intervention:verbal, written,audiovisual information. Evaluation of knowledge of prescribed drugs. 3. Behavioral counseling.training patients to participate in their own care, while positively modifying their skills or routines (i.e. pill boxes,calendars,specific measures to remind the patient taking drugs,adapt the regimen to atient's daily routine). 4. Socio-psycho-affective interventions. 5. Reminder systems: phone,email,alarm on the mobile phone. 6. Simplification as far as possible of therapeutic scheme. 7. Explanation of prescribed medications (name\&dosage), correct intake. 8. Explanation of possible side effects and what to do if they happen. Facilitate a contact. 9. Advise and training on home blood pressure self-measurement. 10. Verbal, written and/or audiovisual information and the online patients'section of scientific societies addresses will be provided.

Sponsors & Collaborators

  • Fondo de Investigacion Sanitaria

    collaborator OTHER

  • Parc de Salut Mar

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-01
Primary Completion
2023-12-20
Completion
2023-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04464746 on ClinicalTrials.gov